Research programme: kinase inhibitors - Nerviano Medical Sciences
Alternative Names: NMS-P715; NMS-P948; PHA-680626; PHA-680632Latest Information Update: 28 Jan 2023
Price :
$50 *
At a glance
- Originator Nerviano Medical Sciences
- Class Antineoplastics; Quinazolines; Small molecules
- Mechanism of Action Anaplastic lymphoma kinase inhibitors; Aurora kinase A inhibitors; Aurora kinase B inhibitors; Aurora kinase C inhibitors; Bcr-Abl tyrosine kinase inhibitors; CDC7 protein kinase inhibitors; Fms-like tyrosine kinase 3 inhibitors; Macrophage colony-stimulating factor receptor antagonists; Phosphotransferase inhibitors; Proto-oncogene protein c-kit inhibitors; TTK protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Jan 2023 No recent reports of development identified for preclinical development in Cancer in Italy (PO)
- 12 Dec 2018 Preclinical development is ongoing in Italy (Nerviano Medical Sciences pipeline, December 2018)
- 28 May 2018 No recent reports of development identified for preclinical development in Cancer in Italy (PO)